Ben Marsh

Ben Marsh

Partner
Ben Marsh
New York
+1 212 813 8816

Ben Marsh, a partner in Goodwin’s Life Sciences and Technology groups and a member of the Capital Markets practice, advises US and international issuers and underwriters on a broad range of capital markets transactions across life sciences, technology, fintech, cleantech, and other sectors. He complements his legal practice with his extensive experience as an equity capital markets investment banker. Ben focuses on initial public offerings and other public listings, including deSPACs, reverse mergers and direct listings, and other public and private corporate finance transactions, including equity, equity-linked, debt, preferred and structured transactions. He also advises public and private companies on a range of corporate governance, investor relations and other corporate matters.

Representative Matters

  • The underwriters of KalVista Pharmaceuticals’ $160 million follow-on public offering of common stock and pre-funded warrants
  • The agents in Silence Therapeutics’ $120 million private placement (PIPE) of American Depositary Shares
  • Orchard Therapeutics in its $478 million acquisition by Kyowa Kirin
  • The underwriters of Myriad Genetics’ $127 million follow-on public offering of common stock
  • The initial purchasers of Enovis Corporation’s $460 million 3.875% convertible senior notes offering
  • The initial purchasers of Amphastar Pharmaceuticals’ $345 million 2.00% convertible senior notes offering
  • COMPASS Pathways in an up to $285 million private placement (PIPE) of American Depositary Shares and warrants to purchase American Depositary Shares 
  • The agent in Taysha Gene Therapies’ $150 million private placement (PIPE) of common stock and pre-funded warrants
  • The underwriters of CorMedix Inc.’s $40 million follow-on offering of common stock and pre-funded warrants
  • Karuna Therapeutics in its $400 million at-the-market (ATM) offering of common stock
  • The initial purchasers of Zynex Inc.’s $60 million convertible senior notes offering
  • The underwriters of Silence Therapeutics’ $56 million follow-on offering of American Depositary Shares
  • Orchard Therapeutics in its up to $188 million private placement (PIPE) strategic financing transaction of ordinary shares and warrants
  • The underwriters in multiple secondary follow-on public offerings of Privia Health Group shares totaling over $1.2 billion
  • The agents in connection with the tax-free distribution of Ligand Pharmaceutical’s OmniAb antibody discovery business and the business combination of OmniAb Inc. with Avista Public Acquisition Corp. II and related deSPAC transaction
  • The agent of Ligand Pharmaceutical’s $100 million at-the-market offering
  • Amylyx Pharmaceuticals in its $190 million initial public offering and in its subsequent $246 million follow on public offering
  • The agent of Calliditas Therapeutics’ $75 million at-the-market offering of American Depositary Shares
  • Amylyx Pharmaceuticals in its $190 million initial public offering
  • The underwriters of Bionomics’ $23 million initial public offering of American Depositary Shares
  • The agent of Silence Therapeutics’ $100 million at-the-market offering of American Depositary Shares
  • COMPASS Pathways in its $144 million follow-on public offering of American Depositary Shares and $150 million at-the-market offering of American Depositary Shares
  • The agent of VBI Vaccines’ $125 million at-the-market offering 
  • The initial purchasers of Dynavax’s $200 million convertible senior notes offering
  • The underwriters of Privia Health Group’s $608 million initial public offering, inclusive of a $92 million concurrent private investment by Anthem, Inc.
  • Orchard Therapeutics in its $150 million PIPE transaction
  • The underwriters of BeyondSpring’s $86 million, $30 million and $25 million follow-on public offerings
  • The underwriters of Royalty Pharma’s $2.5 billion initial public offering and $728 million follow-on public offering
  • COMPASS Pathways in its $147 million initial public offering 
  • The initial purchasers of Royalty Pharma’s $6 billion and $1.3 billion senior unsecured notes offerings
  • Checkmate Pharmaceuticals in its $75 million initial public offering and $50 million at-the-market offering
  • The underwriters of ACell Inc’s initial public offering (withdrawn)
  • The underwriters of Agile Therapeutics’ $45 million follow-on public offering
  • argenx SE in its $557 million follow-on public offering
  • The underwriters of eHealth’s $227 million follow-on public offering and $130 million inaugural follow-on public offering* 
  • BeiGene in its $900 million global public offering*
  • ConforMIS’ $155 million initial public offering*
  • ProQr Therapeutics’ $112 million initial public offering*
  • Vascular Biogenics’ $40 million initial public offering*
  • Evogene’s $85 million initial public offering*
  • Retrophin’s $150 million follow-on public offering*
  • AMAG Pharmaceuticals’ $201 million follow-on public offering*
  • Sarepta Therapeutics’ $101 million follow-on public offering*
  • Syndax Pharmaceuticals’ $53 million initial public offering*

*Denotes experience prior to joining Goodwin.

  • PTC Inc. in a $827 million secondary block trade of its common stock
  • The Underwriters of FTC Solar’s $258 million initial public offering
  • SoFi Technologies in its business combination with Social Capital Hedosophia and related deSPAC transaction for a transaction value of $8.65 billion
  • Verra Mobility’s $187 million inaugural public offering*
  • The Underwriters of GreenSky’s $1.01 billion initial public offering* 
  • The Underwriters on multiple follow-on public offerings by Kornit Digital* 
  • YuMe’s $46 million initial public offering*
  • Trulia’s $117 million initial public offering and $230 million follow-on public offering* 
  • ExactTarget’s $186 million initial public offering and $194 million follow-on public offering*
  • Ambarella’s $41 million initial public offering*
  • Kayak Software’s $105 million initial public offering*
  • Bazaarvoice’s $131 million initial public offering and $131 million follow-on public offering*
  • LifeLock’s $184 million initial public offering*
  • Boingo’s $78 million initial public offering*

*Denotes experience prior to joining Goodwin.

  • Celsius Holdings’ $462 million follow-on public offering
  • Del Frisco’s Restaurant Group’s $75 million initial public offering and $83 million, $147 million and $121 million follow-on public offerings*
  • Amira Nature Foods’ $90 million initial public offering*

*Denotes experience prior to joining Goodwin.

  • The underwriters of VSE Corporation’s $138 million follow-on public offering
  • The underwriters of Ducummon Incorporated’s $92 million re-IPO
  • Advance Disposal Service’s $380 million initial public offering*
  • Atkore International Group’s $192 million initial public offering*
  • SiteOne Landscape Supply’s $242 million initial public offering*
  • Ryerson Holding’s $121 million initial public offering*
  • Metaldyne Performance Group’s $172 million initial public offering*
  • Colfax Corp.’s $633 million and $509 million follow-on public offerings*
  • Constellium’s $376 million initial public offering and $342 million follow-on public offering*
  • Armstrong World Industries’ $624 million follow-on public offering* 
  • TriMas Corp.’s $37 million follow-on public offering*

*Denotes experience prior to joining Goodwin.

  • Tremont Mortgage Trust’s $70 million initial public offering and concurrent private placement*
  • Ladder Capital’s $259 million initial public offering and various follow-on equity and debt offerings* 
  • Multiple public offerings by NorthStar Realty Finance* 
  • Multiple public offerings by Kennedy-Wilson Holdings* 
  • Ramco Gershenson Properties Trust’s $150 million and $114 million follow-on public offerings and $150 million at-the-market offering* 
  • Strategic Hotels and Resorts’ $115 million follow-on public offering*
  • Multiple follow-on public offerings by Armour Residential REIT*
  • Boyd Gaming Corp.’s $228 million follow-on public offering*
  • Isle of Capri Casinos’ $63 million follow-on public offering*

*Denotes experience prior to joining Goodwin.

  • Byline Bancorp’s $145 million initial public offering*
  • Eagle Point Credit’s $100 million initial public offering and $25 million follow-on public offering*
  • Oxford Lane Capital’s $68 million rights offering and $53 million follow-on public offering*
  • Fly Leasing’s $184 million follow-on public offering*
  • Solar Senior Capital’s $160 million initial public offering*
  • Multiple public offerings by TCP Capital*
  • TICC Capital’s $61 million follow-on public offering*

*Denotes experience prior to joining Goodwin.

  • Univar’s $886 million initial public offering and concurrent private placement*
  • Pioneer Natural Resources’ $951 million follow-on public offering*
  • Tallgrass Energy Partners’ $569 million follow-on public offering*
  • PBF Energy’s $540 million follow-on public offerings*
  • NGL Energy Partners’ $300 million inaugural follow-on public offering*

*Denotes experience prior to joining Goodwin.

 

Professional Experience

Ben previously practiced at Skadden Arps Slate Meagher & Flom LLP. He began his legal career at Davis Polk & Wardwell LLP and was also a vice president and associate general counsel in Goldman Sachs’ Investment Banking Division’s legal group. Ben also spent nearly a decade as an investment banker, serving as a director in the Equity Capital Markets group at Deutsche Bank and, prior to that, at Lehman Brothers/Barclays. As an ECM banker, Ben led the execution of initial public offerings and other equity transactions across all industry sectors.

Credentials

Education

JD1999

University of Pennsylvania Law School

(Editor, Journal of Labor and Employment Law; Herman J. Lazarus Award winner; author, Corporate Shell Games)

BA1993

Hamilton College

(cum laude)

Admissions

Bars

  • New York

Publications

  • Co-author, “US Capital Markets Face Uncertainty Entering 2019,” JD Supra, January 2019
  • Co-author, “US Capital Markets Expected to Remain Robust in 2018,” The CLS Blue Sky Blog, February 2018
  • Speaker, “Pocket MBA 2017: Finance for Lawyers and Other Professionals,” Practising Law Institute’s Pocket MBA, 2017
  • Co-author, “Volatility and Uncertainty Continue in the US Capital Markets,” JD Supra, January 2017